

## *Supplementary Material*

### 1 Supplementary Figures and Tables

**Table S1.** Final concentrations of components in collection medium for nasal brushings.

<b>Component</b>	<b>Final Concentration</b>
LHC Basal Medium (ThermoFisher Scientific, Cat. #12-677-019)	Base Media
Penicillin Streptomycin (Penicillin: 10,000U/mL, Streptomycin: 10,000 µg/mL) (ThermoFisher Scientific, Cat. #15140-122)	200 µg/mL
Gentamicin (50mg/mL) (ThermoFisher Scientific, Cat. #15750-060)	20 µg/mL
Amphotericin B (250µg/mL) (ThermoFisher Scientific, Cat. #15290-018)	2.5 µg/mL

**Table S2.** Final concentrations of media components in the Vertex ALI Differentiation Medium (V-ALI).

<b>Component</b>	<b>Final Concentration</b>
Base Media	100% DMEM/F12
Ultroser G	2%
Fetal Clone II	2%
Bovine Brain Extract	0.0225 mg/mL
Triiodothyronine (T3)	0.5 µM
Transferrin	0.03125 µM
Ethanolamine	0.25 µM
Phosphorylethanolamine	0.25 µM
Hydrocortisone	0.02 µM
Epinephrine	1.5 µM
Insulin	0.435 µM
Retinoic Acid	0.01 µM
Penicillin Streptomycin	100 µg/mL

**Figure S1. Expansion of CF nasal cells in EpiX™ medium.** Population doubling per day in CF cultures from five donors. Isolated primary human nasal cells from nasal brushings were grown in EpiX™ medium. Population doublings were maintained between 0.5-1 per day at passages 1, 2, 3, 4, 5, 6, and 7.

**Figure S2. Personalized ion transport measurement of EpiX™-expanded CF nasal cultures from a 6-year-old CF patient with F508del/R117H-7T genotype.** 2D-Planar nasal cultures were generated from EpiX™-propagated cells (P3/8.7PD). **A.** Overview recording. Short circuit current trace ( $I_{sc}$ ,  $\mu\text{A}/\text{cm}^2$ ) recorded in Ussing chamber in presence of a serosal to mucosal Cl gradient.  $I_{sc}$  was measured in response to amiloride (Amilo; 100  $\mu\text{M}$ , apical), followed by forskolin (Fsk; 10  $\mu\text{M}$ , serosal) and VX-770 (1  $\mu\text{M}$ , apical). To reassure complete block of CFTR activity for accurate quantification of mutant CFTR activity, three different CFTR inhibitors were added sequentially (black arrows; CFTRinh172: 50-100  $\mu\text{M}$ ; apical. PPQ102: 50-100  $\mu\text{M}$ , apical; GlyH101: 50  $\mu\text{M}$ , apical). CaCC activity was measured in response to ATP (500  $\mu\text{M}$ , apical). To visualize transepithelial resistance (TER), a marker of epithelial barrier function, upward current deflections (caused by 1 mV voltage pulses, applied for a duration of 1 s and every 60s) are included in the original recording. The recording shown was obtained from a VX-809 treated tissue at ALI day 26 and was selected as a representative trace of n=13 experiments. **B-D.** Quantification of transepithelial electrical resistance (TER), ENaC, CFTR and CaCC activities of non-treated (n=5) cultures (ctr) and cultures treated overnight with CFTR corrector VX-809 (n=4) or VX-661 (n=4). **B.** Transepithelial resistance values ( $R_T$ , in  $\Omega\cdot\text{cm}^2$ ) were taken before amiloride was added and were similar among groups **C.**  $I_{sc}$  changes in response to amiloride ( $\Delta I_{Amilo}$ ) were similar among groups. **D.** CFTR activity was estimated from the maximal inhibition of the forskolin plus VX-770-stimulated  $I_{sc}$  by CFTR inhibitors. CFTR activity was increased in the VX-809 treated group. **E.** ATP-induced chloride secretory responses ( $\Delta I_{ATP}$ ) were measured at peak values and were similar among groups. Data are presented as mean values  $\pm$  SE. \*denotes significantly different from control ( $P < 0.05$ , Holm-Sidak)

**Figure S3. Personalized ion transport measurement of EpiX™-expanded CF nasal cultures from a 17-year-old CF patient with F508del/F508del genotype.** 2D-Planar nasal cultures were generated from EpiX™-propagated cells (P3/10.4PD). **A.** Overview recording. Short circuit current trace ( $I_{sc}$ ,  $\mu\text{A}/\text{cm}^2$ ) recorded in Ussing chamber in presence of a serosal to mucosal Cl gradient.  $I_{sc}$  was measured in response to amiloride (Amilo; 100  $\mu\text{M}$ , apical), followed by forskolin (Fsk; 10  $\mu\text{M}$ , serosal) and VX-770 (1  $\mu\text{M}$ , apical). To reassure complete block of CFTR activity for accurate quantification of mutant CFTR activity, three different CFTR inhibitors were added sequentially (black arrows; CFTRinh172: 50-100  $\mu\text{M}$ ; apical. PPQ102: 50-100  $\mu\text{M}$ , apical; GlyH101: 50  $\mu\text{M}$ , apical). CaCC activity was measured in response to ATP (500  $\mu\text{M}$ , apical). To visualize transepithelial resistance (TER), a marker of epithelial barrier function, upward current deflections (caused by 1 mV voltage pulses, applied for a duration of 1 s and every 60s) are included in the original recording. The recording shown was obtained from a non-treated culture at ALI day 25 and was selected as a representative trace of n=13 experiments. **B-D.** Quantification of transepithelial electrical resistance (TER), ENaC and CaCC activities of non-treated (n=5) cultures (ctr) and cultures treated overnight with CFTR corrector VX-809 (n=4) or VX-661 (n=4). **B.** Transepithelial resistance values ( $R_T$ , in  $\Omega\cdot\text{cm}^2$ ) were taken before amiloride was added. **C.** Current changes in response to amiloride ( $\Delta I_{Amilo}$ ) were similar among groups. **D.** CFTR activity was estimated from the maximal inhibition of the forskolin plus VX-770-stimulated  $I_{sc}$  by CFTR inhibitors. Average CFTR activity

was not significantly different among groups. **E.** ATP-induced chloride secretory responses ( $\Delta I_{ATP}$ ) were measured at peak values and were similar among group. Data are presented as mean values $\pm$ SE.

**Figure S4. Personalized ion transport measurement of EpiX<sup>TM</sup>-expanded CF nasal cultures from a 20-year-old CF patient with F508del/c.850dupA genotype.** 2D-Planar nasal cultures were generated from EpiX<sup>TM</sup>-propagated cells (P4/11.4PD). **A.** Overview recording. Short circuit current trace ( $I_{sc}$ ,  $\mu A/cm^2$ ) recorded in Ussing chamber in presence of a serosal to mucosal Cl gradient.  $I_{sc}$  was measured in response to amiloride (Amilo; 100  $\mu M$ , apical), followed by forskolin (Fsk; 10  $\mu M$ , serosal) and VX-770 (1  $\mu M$ , apical). To reassure complete block of CFTR activity for accurate quantification of mutant CFTR activity, three different CFTR inhibitors were added sequentially (black arrows; CFTRinh172: 50-100  $\mu M$ ; apical. PPQ102: 50-100  $\mu M$ , apical; GlyH101: 50  $\mu M$ , apical). CaCC activity was measured in response to ATP (500  $\mu M$ , apical). To visualize transepithelial resistance (TER), a marker of epithelial barrier function, upward current deflections (caused by 1 mV voltage pulses, applied for a duration of 1 s and every 60s) are included in the original recording. The recording shown was obtained from a VX-809 treated culture at ALI day 27 and was selected as a representative trace of n=8 experiments. **B-D.** Quantification of transepithelial electrical resistance (TER), ENaC and CaCC activities of non-treated (n=2) cultures (ctr) and cultures treated overnight with CFTR corrector VX-809 (n=3) or VX-661 (n=3). **B.** Transepithelial resistance values ( $R_T$ , in  $\Omega cm^2$ ) were taken before amiloride was added and were similar among groups. **C.** Current changes in response to amiloride ( $\Delta I_{Amilo}$ ) were similar among groups. **D.** CFTR activity was estimated from the maximal inhibition of the forskolin plus VX-770-stimulated  $I_{sc}$  by CFTR inhibitors. Average CFTR activity was increased in the VX-809 treated group. **E.** ATP-induced chloride secretory responses ( $\Delta I_{ATP}$ ) were measured at peak values and were similar among groups. Data are presented as mean values $\pm$ SE. \*denotes significantly different from control ( $P<0.05$ , unpaired t-test)

**Figure S5. Personalized ion transport measurement of EpiX<sup>TM</sup>-expanded CF nasal cultures from a 3-year-old CF patient with R334W/406-1G->A genotype.** 2D-Planar nasal cultures were generated from EpiX<sup>TM</sup>-propagated cells (P3/8.7PD). **A.** Overview recording. Short circuit current trace ( $I_{sc}$ ,  $\mu A/cm^2$ ) recorded in Ussing chamber in presence of a serosal to mucosal Cl gradient.  $I_{sc}$  was measured in response to amiloride (Amilo; 100  $\mu M$ , apical), followed by forskolin (Fsk; 10  $\mu M$ , serosal) and VX-770 (1  $\mu M$ , apical). To reassure complete block of CFTR activity for accurate quantification of mutant CFTR activity, three different CFTR inhibitors were added sequentially (black arrows; CFTRinh172: 50-100  $\mu M$ ; apical. PPQ102: 50-100  $\mu M$ , apical; GlyH101: 50  $\mu M$ , apical). CaCC activity was measured in response to ATP (500  $\mu M$ , apical). To visualize transepithelial resistance (TER), a marker of epithelial barrier function, upward current deflections (caused by 1 mV voltage pulses, applied for a duration of 1 s and every 60s) are included in the original recording. The recording shown was obtained from a VX-809 treated culture at ALI day 26 and was selected as a representative trace of n=10 experiments. **B-D.** Quantification of transepithelial electrical resistance (TER), ENaC and CaCC activities of non-treated (n=3) cultures (ctr) and cultures treated overnight with CFTR corrector VX-809 (n=4) or VX-661 (n=3). **B.** Transepithelial resistance values ( $R_T$ , in  $\Omega cm^2$ ) were taken before amiloride was added and were similar among groups. **C.** Current changes in response to amiloride ( $\Delta I_{Amilo}$ ) were large and similar among groups. **D.** CFTR activity was estimated from the maximal inhibition of the forskolin plus VX-770-stimulated  $I_{sc}$  by CFTR inhibitors. Average CFTR activity was not significantly different among groups. **E.** ATP-induced chloride secretory responses ( $\Delta I_{ATP}$ ) were measured at peak values and were similar among groups. Data are presented as mean values $\pm$ SE.

**Figure S6. Personalized ion transport measurement of EpiX™-expanded CF nasal cultures from a 4-year-old CF patient with CFTR~~dele2,3(21kb)~~/CFTR~~dele2,3(21kb)~~ genotype.** 2D-Planar nasal cultures were generated from EpiX™-propagated cells (P3/10.4PD). **A.** Overview recording. Short circuit current trace ( $I_{sc}$ ,  $\mu\text{A}/\text{cm}^2$ ) recorded in Ussing chamber in presence of a serosal to mucosal Cl gradient.  $I_{sc}$  was measured in response to amiloride (Amilo; 100  $\mu\text{M}$ , apical), followed by forskolin (Fsk; 10  $\mu\text{M}$ , serosal) and VX-770 (1  $\mu\text{M}$ , apical). To reassure complete block of CFTR activity for accurate quantification of mutant CFTR activity, three different CFTR inhibitors were added sequentially (black arrows; CFTRinh172: 50-100  $\mu\text{M}$ ; apical. PPQ102: 50-100  $\mu\text{M}$ , apical; GlyH101: 50  $\mu\text{M}$ , apical). CaCC activity was measured in response to ATP (500  $\mu\text{M}$ , apical). The recording was obtained from a VX-809 treated culture at ALI day 22 and was selected as a representative trace of  $n=9$  experiments. **B-D.** Quantification of transepithelial electrical resistance (TER), ENaC and CaCC activities of non-treated ( $n=4$ ) cultures (ctr) and cultures treated overnight with CFTR corrector VX-809 ( $n=2$ ) or VX-661 ( $n=3$ ). **B.** Transepithelial resistance values ( $R_T$ , in  $\Omega\cdot\text{cm}^2$ ) were taken before amiloride was added and were similar among groups **C.**  $I_{sc}$  changes in response to amiloride ( $\Delta I_{Amilo}$ ) were similar among groups. **D.** CFTR-mediated chloride currents ( $\Delta I_{CFTRinh}$ ) were determined by calculating maximal inhibition of the forskolin plus VX-770-stimulated  $I_{sc}$  by CFTR inhibitors. CFTR currents were increased in the VX-661 treated group. **E.** ATP-induced chloride secretory responses ( $\Delta I_{ATP}$ ) were measured at peak values and were similar among groups. Data are presented as mean values  $\pm$  SE. \*denotes significantly different from control ( $P < 0.05$ , Holm-Sidak). **F, G, H.** Detailed recordings of CFTR currents to illustrate CFTR modulator effects on homozygous CFTR~~dele2,3~~ mutation (ALI cultures, day 22). Original traces recorded in presence of amiloride. Axes are scaled the same for all three plots. **F.** Untreated, **G.** VX-809-treated, **H.** VX-661-treated. CFTRinh-blocked currents were  $-0.67 \mu\text{A}/\text{cm}^2$  (nontreated),  $-1.34 \mu\text{A}/\text{cm}^2$  (VX-809), and  $-3.54 -0.67 \mu\text{A}/\text{cm}^2$  (VX-661) suggesting rescue of CFTR~~dele2,3(21kb)~~ by CFTR corrector compounds. Note, size of current deflections indicate that TER values were in a similar range;  $R_T=322 \Omega\cdot\text{cm}^2$  (no corrector),  $R_T=431 \Omega\cdot\text{cm}^2$  (VX-809),  $R_T = 400 \Omega\cdot\text{cm}^2$  (VX-661).

**Figure S7. Personalized ion transport measurements of non-CF cultures.** 2D-Planar cultures were generated from **A.** EpiX™-propagated bronchial epithelial cells (passage 1) from an adult non-CF donor with idiopathic pulmonary fibrosis and **B.** nasal epithelial cells (passage 1) propagated by conditional reprogramming. Expanded cells were differentiated by a similar ALI protocol as previously described (8). **A,B.** Overview recording. Short circuit current trace ( $I_{sc}$ ,  $\mu\text{A}/\text{cm}^2$ ) recorded in Ussing chamber in presence of a serosal to mucosal Cl gradient.  $I_{sc}$  was measured in response to amiloride (Amilo; 100  $\mu\text{M}$ , apical), followed by forskolin (Fsk; 10  $\mu\text{M}$ , serosal) and VX-770 (1  $\mu\text{M}$ , apical). To reassure complete block of CFTR activity for accurate quantification of mutant CFTR activity, three different CFTR inhibitors were added sequentially (black arrows; CFTRinh172: 50-100  $\mu\text{M}$ ; apical. PPQ102: 50-100  $\mu\text{M}$ , apical; GlyH101: 50  $\mu\text{M}$ , apical) in recording A, whereas a single CFTR inhibitor (CFTRinh172) was applied in recording B. CaCC activity was measured in response to ATP (500  $\mu\text{M}$ , apical). To visualize transepithelial resistance (TER), a marker of epithelial barrier function, upward current deflections (caused by 1 mV voltage pulses, applied for a duration of 1 s and every 60s) are included in the original recording. **C-F.** Quantification of transepithelial electrical resistance (TER), CFTR, ENaC and CaCC activities of bronchial and nasal cultures **C.** Transepithelial resistance values ( $R_T$ , in  $\Omega\cdot\text{cm}^2$ ) were taken before amiloride was added and were lower in the nasal cultures **D.** Current changes in response to amiloride ( $\Delta I_{Amilo}$ ) are small and decreased in the nasal culture. **E.** Block of forskolin-stimulated CFTR current by CFTR inhibitors ( $\Delta I_{Fsk}$ ) are similar among bronchial and nasal cultures **F.** ATP-induced chloride secretory responses ( $\Delta I_{ATP}$ ) were plotted from peak values and were similar among groups. Data are presented

as mean values $\pm$ SE (n=3-12 experiments). \*denotes significantly different between groups ( $P\leq 0.05$ , t-test).